Newshot

Science Corporation’s brain tech is worth $3.5 billion after new funding

Summary

Science Corp raised a $400 million Series D to scale up its anti-blindness business.

Original text(via TechCrunch AI)
Tim Fernholz
Tim Fernholz
  • Tim Fernholz

Science Corporation’s brain tech is worth $3.5 billion after new funding

Science Corporation, the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post.

Investors in the new round valued the company at $3.5 billion, a person familiar with the deal told TechCrunch. Those backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

Hodak, who talked his way into a graduate neuroscience lab as a college student and has pursued biotechnology ever since, co-founded Science to leverage new technologies to understand and interact with the brain.

Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, as well as being trialled for new conditions.

Hodak announced that the device is now being trialled for patients with another blindness-causing condition, Stargardt’s disease, while onstage at TechCrunch Disrupt.

With the funding, the company aims to bring the device to the United States through the FDA’s Humanitarian Device Exemption, which lets experimental medical technology be used to treat rare conditions. Science has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to let them seek approval to use the device on people in the US.

Still, the startup’s big ambition and founding purpose is connecting directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. The company is currently designing initial human trials of the device with Yale neurosurgery professor Murat Günel, who told TechCrunch it could offer potential treatments for Parkinson’s disease, among other brain injuries and illnesses.

Get an Early Peek at the Next TechCrunch DisruptDisrupt, Startup Battlefield, and more will return next year, and you can be at the front of the line.Sign up for our waitlist

Newsletters

Subscribe for the industry’s biggest tech news

Related

  • Apps Spotify’s new tool aims to stop deepfakes from being attributed to real artists Aisha Malik 27 minutes ago

Spotify’s new tool aims to stop deepfakes from being attributed to real artists

  • Robotics Genesis AI raises $500 million to deploy glove-wearing robots Tim Fernholz 27 minutes ago
Genesis AI CEO and co-founder Zhou Xian with Eno, the company's flagship robot.
Genesis AI CEO and co-founder Zhou Xian with Eno, the company's flagship robot.

Genesis AI raises $500 million to deploy glove-wearing robots

  • Tim Fernholz
  • Biotech & Health Upside Foods can now make a million pounds of chicken a year without killing any animals Amanda Silberling 27 minutes ago

Upside Foods can now make a million pounds of chicken a year without killing any animals

  • Amanda Silberling

Latest in Biotech & Health

  • In Brief Science Corporation’s brain tech is worth $3.5 billion after new funding Tim Fernholz 10 seconds ago

Science Corporation’s brain tech is worth $3.5 billion after new funding

  • Tim Fernholz
  • Biotech & Health Upside Foods can now make a million pounds of chicken a year without killing any animals Amanda Silberling 27 minutes ago

Upside Foods can now make a million pounds of chicken a year without killing any animals

  • Amanda Silberling
  • Biotech & Health Whoop just launched a social network Connie Loizos Nov 12, 2026
Whoop band and app displayed on smartphone screen
Whoop band and app displayed on smartphone screen

Whoop just launched a social network

  • Connie Loizos

The text above was extracted automatically from the source page and may miss images, tables or code blocks. The original is authoritative.

Published by TechCrunch AI
This site only summarises and aggregates; copyright stays with the original author. Headlines and summaries follow the source — where they differ, the original wins.
Read the original ↗